These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys?

Amgen and Roche reported strong phase‑2 anti‑obesity data that could meaningfully expand their product portfolios: Amgen’s MariTide produced up to ~20% mean weight loss in a 52‑week trial and is entering phase‑3 across diabetes and weight management with potential approval within ~3 years, while Roche’s CT‑388 achieved a placebo‑adjusted 22.5% weight loss at the highest dose in 48 weeks and is moving into two phase‑3 obesity trials this quarter (with CT‑996 as a potential oral follow‑on). The positives bolster both firms’ growth outlooks amid Amgen’s 2025 loss of denosumab exclusivity, but management pipelines and existing drivers (Amgen’s bemarituzumab, rocatinlimab, Tezspire, Repatha; Roche’s Tecentriq, Vabysmo) support longer‑term revenue visibility and investor appeal, alongside Amgen’s steady dividend policy.

Analysis

Market structure: Winners are Amgen (AMGN) and Roche (RHHBY OTC) as pipeline entrants with differentiated dosing (monthly MariTide) and strong phase‑2 efficacy (CT‑388 ~22.5% placebo‑adj). Incumbents (Novo Nordisk, Eli Lilly) face incremental share erosion in the 2026–2030 window; payers and reinsurance administrators become gatekeepers to real uptake. Expect pricing pressure on weekly GLP agents and segmentation by dosing convenience rather than pure efficacy over 3 years.

Risk assessment: The dominant tail risks are binary phase‑3/regulatory failure (estimate 30–50% single‑asset clinical risk per candidate), post‑launch payer restrictions, or unexpected safety signals that could compress assumed revenue by 30–70% versus base case. Near term (days–weeks) volatility will track trial starts/announcements; medium term (6–18 months) readouts and payer guidance drive realized value; long term (3–5 years) depends on formulary share and manufacturing scale.

Trade implications: Favor modest directional exposure to AMGN and RHHBY sized to program risk: 2–3% long positions each, with 12–18 month time horizons and 12–15% stop losses. Use 12–18 month call spreads ~20–30% OTM (size 1%–2% each) to lever upside into phase‑3/approval catalysts while capping premium. Implement a hedge pair: long AMGN / short LLY at 0.5x notional to neutralize GLP market beta through 2026.

Contrarian angles: Consensus underestimates payer resistance and manufacturing bottlenecks — historical analogs (PCSK9 launches) show initial uptake can be 40–60% below optimistic models for 12–24 months. The market may be overpricing a smooth approval path; a 10–20% pullback on any safety/label uncertainty would be an attractive add point. Monitor enrollment pace, interim safety signals, and CMS coverage decisions in the next 30–90 days as primary triggers.

Key Decisions for Investors

• Establish a 2.5% net long position in AMGN (ticker AMGN) sized to total portfolio risk appetite; target 20–35% upside over 12–36 months if MariTide advances through phase‑3 and gains payer access. Place a stop‑loss at 15% and consider trimming 50% of the position on a 30% move higher.
• Establish a 2% net long position in Roche (RHHBY OTC) ahead of phase‑3 starts for CT‑388; horizon 12–36 months. Hedge currency exposure if you hold non‑CHF base currency and set a 12% stop‑loss; add on a 10% pullback.
• Buy 12–18 month call spreads (limit premium to 1–2% of portfolio each) on AMGN and RHHBY ~20–30% OTM to capture asymmetric upside into phase‑3/approval catalysts while capping downside. Roll or monetize on positive interim data or regulatory submission.
• Implement a relative value hedge: long AMGN / short LLY at 0.5x notional through end‑2026 to reduce GLP market directional risk. Rebalance if LLY/AMGN implied volatility diverges by >30% or after major trial readouts.
• Reduce small‑cap obesity/GLP biotech exposure by 50% and redeploy 1–3% into large‑cap diversified pharma and IG pharma credit (increase IG pharma allocation by 50–100 bps) to favor balance‑sheet strength and diversified revenue streams while transplantation of obesity revenues matures.